NLVP
RCKT icon

New Leaf Venture Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

New Leaf Venture Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150,706
Closed -$1.01M – 9
2025
Q1 		$1.01M Hold
150,706
– – 2.24% 6
2024
Q4 		$1.89M Hold
150,706
– – 2.53% 6
2024
Q3 		$2.78M Hold
150,706
– – 2.86% 5
2024
Q2 		$3.24M Buy
150,706
+32,464
+27% +$746K 3.95% 5
2024
Q1 		$3.19M Hold
118,242
– – 2.79% 7
2023
Q4 		$3.54M Hold
118,242
– – 2.85% 7
2023
Q3 		$2.42M Hold
118,242
– – 3.11% 7
2023
Q2 		$2.35M Hold
118,242
– – 2.02% 8
2023
Q1 		$2.03M Hold
118,242
– – 1.67% 12
2022
Q4 		$2.31M Buy
+118,242
New +$2.18M 1.68% 11
2017
Q1 		– Sell
-15,575
Closed -$380K – 18
2016
Q4 		$380K Buy
15,575
+3,000
+24% +$85.6K 0.27% 15
2016
Q3 		$477K Buy
+12,575
New +$395K 0.34% 13

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

New Leaf Venture Partners's RCKT Position: Q2 2025 in Review

New Leaf Venture Partners sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 150,706 shares — an estimated $1.01M sold.

New Leaf Venture Partners first reported a position in RCKT in Q3 2016 and held it in 12 quarters. The position peaked at $3.54M in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • New Leaf Venture Partners reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • New Leaf Venture Partners sold 150,706 Rocket Pharmaceuticals shares in Q2 2025, an estimated $1.01M.
  • New Leaf Venture Partners first reported a position in Rocket Pharmaceuticals in Q3 2016 and held it in 12 quarters.
  • New Leaf Venture Partners's Rocket Pharmaceuticals position peaked at $3.54M in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on New Leaf Venture Partners's 13F filing for Q2 2025, filed 13 Aug 2025.